APA (7th ed.) Citation

H, T., ST, B., S, F., P, P., J, B., A, P., & KS, T. (2025). Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling. Pharmaceutics, 17(4), . https://doi.org/10.3390/pharmaceutics17040531

Chicago Style (17th ed.) Citation

H, Tracey, Bate ST, Ford S, Patel P, Bloomer J, Patel A, and Taskar KS. "Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling." Pharmaceutics 17, no. 4 (2025). https://doi.org/10.3390/pharmaceutics17040531.

MLA (9th ed.) Citation

H, Tracey, et al. "Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling." Pharmaceutics, vol. 17, no. 4, 2025, https://doi.org/10.3390/pharmaceutics17040531.